Cotellic 20 mg film-coated tablets

DRUG7 trials

Sponsors

Oslo University Hospital HF, F. Hoffmann-La Roche AG, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Rigshospitalet, Centre Leon Berard

Conditions

Advanced CancerAdvanced solid tumorCancerCohort-1/Phase-B and Cohort-3) are allowed to start vemurafenib with or without cobimetinib immediatelyMultiple myelomaNon-Hodgkin lymphomaPersistent or Recurrent Rare Epithelial Ovarian TumorsT-cell prolymphocytic leukemia

Phase 1

COTESARC : A multicentre, open-label, Phase I-II study evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advanced and/or metastatic soft tissue sarcoma

RecruitingCTIS2024-510712-75-00

Centre Leon Berardadvanced / metastatic

Start: 2020-02-12Target: 80Updated: 2024-12-04

Phase 2

A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors

Active, not recruitingCTIS2023-508194-89-00

F. Hoffmann-La Roche AGPersistent or Recurrent Rare Epithelial Ovarian Tumors

Start: 2021-08-30Target: 57Updated: 2026-01-06

A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)

RecruitingCTIS2023-509152-33-00

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAdvanced solid tumor, Multiple myeloma, Non-Hodgkin lymphoma +1

Start: 2016-07-25Target: 3000Updated: 2025-12-19

ProTarget - A Danish Nationwide Clinical Trial on Targeted Anti‐Cancer Treatment based on Genomic Profiling

RecruitingCTIS2023-510527-29-00

RigshospitaletCancer

Start: 2020-09-01Target: 600Updated: 2025-04-25

Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway

RecruitingCTIS2023-507894-16-00

Oslo University Hospital HFCancer

Start: 2021-04-01Target: 6000Updated: 2026-01-22

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile

Not yet recruitingCTIS2024-517478-68-01

HUS-YhtymaeAdvanced Cancer

Target: 250Updated: 2024-11-06

STEP-WISE COMBINATION OF OBINUTUZUMAB, VEMURAFENIB AND COBIMETINIB IN PATIENTS WITH HAIRY CELL LEUKEMIA (HCL) PREVIOUSLY TREATED WITH PURINE ANALOGS OR UNFIT FOR CHEMOTHERAPY: A PHASE-2, SINGLE-ARMS, ITALIAN, MULTICENTER STUDY (HCL-PG04)

Not yet recruitingCTIS2024-520121-36-00

Universita' Degli Studi Di Perugiabut not limited to, Cohort-1/Phase-B and Cohort-3) are allowed to start vemurafenib with or without cobimetinib immediately, infectious complications +9

Target: 50Updated: 2025-01-28

Related Papers

Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol.

2025-12-01

Data from Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol

2025-12-01